Article
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
International journal of molecular sciences - 9 Aug 2022
Cincotta Anthony H, Cersosimo Eugenio, Alatrach Mariam, Ezrokhi Michael, Agyin Christina, Adams John, Chilton Robert, Triplitt Curtis, Chamarthi Bindu, Cominos Nicholas, DeFronzo Ralph A
Abstract excerpt
Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms. However, a chronic state of elevated sympathetic nervous system activity and central hypodopaminergic function has been demonstrated to potentiate an immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.